Stephen M Kaminsky

List of Publications by Year
in descending order

87 papers	3,856 citations	159525 30 h-index	128225 60 g-index
91 all docs	91 docs citations	91 times ranked	4606 citing authors

#	Article	IF	Citations
1	Genetic Modification of the AAV5 Capsid with Lysine Residues Results in a Lung-Tropic Liver-Detargeted Gene Transfer Vector. Human Gene Therapy, 2022, 33, 148-154.	1.4	2
2	Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. Human Gene Therapy, 2021, 32, 563-580.	1.4	18
3	Automated Retinal Layer Segmentation in CLN2-Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy. Translational Vision Science and Technology, 2021, 10, 23.	1.1	2
4	Longâ€term functional correction of cystathionine Î²â€synthase deficiency in mice by adenoâ€associated viral gene therapy. Journal of Inherited Metabolic Disease, 2021, 44, 1382-1392.	1.7	7
5	Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy. Human Gene Therapy, 2020, 31, 57-69.	1.4	13
6	Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy. Human Gene Therapy, 2020, 31, 819-827.	1.4	23
7	Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates. Human Gene Therapy, 2020, 31, 1237-1259.	1.4	21
8	Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. Science Translational Medicine, 2020, 12, .	5.8	35
9	Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. Ophthalmology Retina, 2020, 4, 728-736.	1.2	14
10	Gene therapy for alpha 1-antitrypsin deficiency with an oxidant-resistant human alpha 1-antitrypsin. JCI Insight, 2020, 5, .	2.3	12
11	Cocaine vaccine dAd5GNE protects against moderate daily and high-dose â€œbingeâ€•cocaine use. PLoS ONE, 2020, 15, e0239780.	1.1	18
12	Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 1081-1089.	2.7	31
13	Accurate Quantification and Characterization of Adeno-Associated Viral Vectors. Frontiers in Microbiology, 2019, 10, 1570.	1.5	72
14	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2019, 7, 473-500.	0.5	20
15	Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. Experimental Neurology, 2018, 306, 22-33.	2.0	16
16	AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. Human Gene Therapy Clinical Development, 2018, 29, 24-47.	3.2	90
17	Biology of the Adrenal Gland Cortex Obviates Effective Use of Adeno-Associated Virus Vectors to Treat Hereditary Adrenal Disorders. Human Gene Therapy, 2018, 29, 403-412.	1.4	29
18	In Vivo Potency Assay for Adeno-Associated Virusâ€“Based Gene Therapy Vectors Using AAVrh.10 as an Example. Human Gene Therapy Methods, 2018, 29, 146-155.	2.1	18

#	Article	IF	Citations
19	Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Scientific Reports, 2018, 8, 15229.	1.6	21
20	Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. Chronic Obstructive Pulmonary Diseases (Miami, Fla), 2018, 5, 244-257.	0.5	14
21	In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration. Journal of Thoracic and Cardiovascular Surgery, 2017, 153, 329-339.e3.	0.4	43
22	Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. Journal of Allergy and Clinical Immunology, 2016, 138, 1652-1662.e7.	1.5	33
23	Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. Journal of Neuroscience, 2016, 36, 12425-12435.	1.7	53
24	309. Optimization of Production of AAVrh.10 Viral Vectors. Molecular Therapy, 2016, 24, S124-S125.	3.7	0
25	36. Translation of an Adenovirus-Based Cocaine Vaccine dAd5GNE to a Clinical Trial. Molecular Therapy, 2016, 24, S16.	3.7	5
26	365. Long-Term Toxicology Evaluation of AAVrh. 10hARSA Administration to the CNS of Nonhuman Primates to Treat Metachromatic Leukodystrophy. Molecular Therapy, 2016, 24, S146.	3.7	3
27	471. In Vivo Potency Assay for AAV-Based Gene Therapy Vectors. Molecular Therapy, 2016, 24, S186.	3.7	1
28	474. Consequences of Infusion Time on Efficiency of Intravenous Delivery of Vector Genomes to the Liver. Molecular Therapy, 2016, 24, S187.	3.7	1
29	755. One-time Gene Therapy for Hereditary Angioedema. Molecular Therapy, 2016, 24, S298-S299.	3.7	3
30	Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques. Pharmacology Biochemistry and Behavior, 2016, 150-151, 76-86.	1.3	46
31	Brain Regionâ€“Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). American Journal of Neuroradiology, 2016, 37, 1160-1169.	1.2	19
32	Gene therapy for metachromatic leukodystrophy. Journal of Neuroscience Research, 2016, 94, 1169-1179.	1.3	64
33	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiology of Aging, 2016, 44, 159-172.	1.5	59
34	Adenovirus-Based Vaccines for the Treatment of Substance Use Disorders. , 2016, , 229-248.		1
35	Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. PLoS ONE, 2016, 11, e0162978.	1.1	19
36	Gene Therapy for Inborn Errors of Metabolism: Batten Disease. , 2016, , 111-129.		0

#	Article	IF	Citations
37	51. Rapid and Long Term Protection to Pseudomonas aeruginosa Using a Platform Vaccine Concept That Mediates Both Passive and Active Immunity. Molecular Therapy, 2015, 23, S22-S23.	3.7	0
38	387. Gene Delivery of APOE2 Reduces Amyloid Pathology in Transgenic Mouse Models of Alzheimer's Disease. Molecular Therapy, 2015, 23, S154.	3.7	0
39	444. One-Time Gene Therapy to Prevent Peanut-Induced Anaphylaxis. Molecular Therapy, 2015, 23, S176.	3.7	0
40	455. Safety of Vaccination to Treat Cocaine Addiction with Capsid Proteins from a Disrupted Adenovirus Conjugated to a Cocaine Analog. Molecular Therapy, 2015, 23, S180-S181.	3.7	1
41	596. AAV Gene Delivery of the Anti-Tau Antibody PHF1 Reduces Brain Tau Pathology in P301L Mice. Molecular Therapy, 2015, 23, S237.	3.7	0
42	718. AAV-Mediated Local Anti-EGFR Antibody Gene Expression in CNS Delays Tumor Growth and Increases Survival in a Human Glioblastoma Xenograft Model. Molecular Therapy, 2015, 23, S287.	3.7	0
43	501. Radioiodinated Adeno-Associated Virus: A Promising New Approach for Monitoring Gene Therapy. Molecular Therapy, 2015, 23, S200.	3.7	0
44	Evaluation of Compounded Bevacizumab Prepared for Intravitreal Injection. JAMA Ophthalmology, 2015, 133, 32.	1.4	42
45	Genetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma. Cancer Gene Therapy, 2015, 22, 1-8.	2.2	21
46	Fate of Systemically Administered Cocaine in Nonhuman Primates Treated with the dAd5GNE Anticocaine Vaccine. Human Gene Therapy Clinical Development, 2014, 25, 40-49.	3.2	51
47	Comparative Efficacy and Safety of Multiple Routes of Direct CNS Administration of Adeno-Associated Virus Gene Transfer Vector Serotype rh.10 Expressing the Human Arylsulfatase A cDNA to Nonhuman Primates. Human Gene Therapy Clinical Development, 2014, 25, 164-177.	3.2	46
48	Phase I/II Study of Intrapleural Administration of a Serotype rh.10 Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human Î±1-Antitrypsin cDNA to Individuals with Î±1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development, 2014, 25, 112-133.	3.2	21
49	AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer. Gynecologic Oncology, 2014, 135, 325-332.	0.6	28
50	â€œTripletâ€•polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors. Journal of Thoracic and Cardiovascular Surgery, 2014, 148, 1656-1664.e2.	0.4	48
51	Gene Therapy to Stimulate Angiogenesis to Treat Diffuse Coronary Artery Disease. Human Gene Therapy, 2013, 24, 948-963.	1.4	28
52	Advances in the treatment of neuronal ceroid lipofuscinosis. Expert Opinion on Orphan Drugs, 2013, 1, 951-975.	0.5	6
53	Disrupted Adenovirus-Based Vaccines Against Small Addictive Molecules Circumvent Anti-Adenovirus Immunity. Human Gene Therapy, 2013, 24, 58-66.	1.4	27
54	Suppression of Nicotine-Induced Pathophysiology by an Adenovirus Hexon-Based Antinicotine Vaccine. Human Gene Therapy, 2013, 24, 595-603.	1.4	21

#	Article	IF	Citations
55	Assessment of Disease Severity in Late Infantile Neuronal Ceroid Lipofuscinosis Using Multiparametric MR Imaging. American Journal of Neuroradiology, 2013, 34, 884-889.	1.2	19
56	Safety of Direct Cardiac Administration of AdVEGF-All6A+, a Replication-Deficient Adenovirus Vector cDNA/Genomic Hybrid Expressing All Three Major Isoforms of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Rats. Human Gene Therapy Clinical Development, 2013, 24, 38-46.	3.2	15
57	Intrapleural Administration of an AAVrh.10 Vector Coding for Human Î±1-Antitrypsin for the Treatment of Î±1-Antitrypsin Deficiency. Human Gene Therapy Clinical Development, 2013, 24, 161-173.	3.2	50
58	Adenovirus Capsid-Based Anti-Cocaine Vaccine Prevents Cocaine from Binding to the Nonhuman Primate CNS Dopamine Transporter. Neuropsychopharmacology, 2013, 38, 2170-2178.	2.8	52
59	Spectrum of Ocular Manifestations inÂCLN2-Associated Batten (Jansky-Bielschowsky)ÂDisease Correlate with Advancing Age and Deteriorating Neurological Function. PLoS ONE, 2013, 8, e73128.	1.1	36
60	AAVrh.10-Mediated Expression of an Anti-Cocaine Antibody Mediates Persistent Passive Immunization That Suppresses Cocaine-Induced Behavior. Human Gene Therapy, 2012, 23, 451-459.	1.4	44
61	Novel Cocaine Vaccine Linked to a Disrupted Adenovirus Gene Transfer Vector Blocks Cocaine Psychostimulant and Reinforcing Effects. Neuropsychopharmacology, 2012, 37, 1083-1091.	2.8	68
62	Double-Blinded, Placebo-Controlled, Randomized Gene Therapy Using Surgery for Vector Delivery. Human Gene Therapy, 2012, 23, 438-441.	1.4	11
63	In VivoGene Transfer Strategies to Achieve Partial Correction of von Willebrand Disease. Human Gene Therapy, 2012, 23, 576-588.	1.4	16
64	AAV-Directed Persistent Expression of a Gene Encoding Anti-Nicotine Antibody for Smoking Cessation. Science Translational Medicine, 2012, 4, 140ra87.	5.8	47
65	Anti-Cocaine Vaccine Based on Coupling a Cocaine Analog to a Disrupted Adenovirus. CNS and Neurological Disorders - Drug Targets, 2011, 10, 899-904.	0.8	35
66	Persistent Suppression of Ocular Neovascularization with Intravitreal Administration of AAVrh.10 Coding for Bevacizumab. Human Gene Therapy, 2011, 22, 1525-1535.	1.4	24
67	Cocaine Analog Coupled to Disrupted Adenovirus: A Vaccine Strategy to Evoke High-titer Immunity Against Addictive Drugs. Molecular Therapy, 2011, 19, 612-619.	3.7	61
68	Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. Journal of Neurosurgery: Pediatrics, 2010, 6, 115-122.	0.8	60
69	P12-14. Design of hydrophilic, helical peptides that mimic the 4E10 epitope of HIV-1 gp41. Retrovirology, 2009, 6, .	0.9	0
70	Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target. Science, 2009, 326, 285-289.	6.0	1,614
71	HIV-1 rational vaccine design: molecular details of b12â€“gp120 complex structure. Expert Review of Vaccines, 2007, 6, 319-321.	2.0	4
72	Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction. Biochimica Et Biophysica Acta - Biomembranes, 2006, 1758, 1071-1077.	1.4	56

#	Article	IF	Citations
73	Surgical Targeting and Focal Implantation of Gene Therapy for Global Neurological Disease: Operative Technique and Nuances. Neurosurgery, 2006, 59, 476.	0.6	0
74	Intracranial Delivery of CLN2 Reduces Brain Pathology in a Mouse Model of Classical Late Infantile Neuronal Ceroid Lipofuscinosis. Journal of Neuroscience, 2006, 26, 1334-1342.	1.7	118
75	315. Identification and Control of Bacterial Contamination in an Academic Good Manufacturing Practice Facility. Molecular Therapy, 2006, 13, S120.	3.7	0
76	Gene Therapy for the Late Infantile Form of Batten Disease. , 2006, , 317-333.		0
77	AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL. Gene Therapy, 2005, 12, 1618-1632.	2.3	74
78	Confronting the Issues of Therapeutic Misconception, Enrollment Decisions, and Personal Motives in Genetic Medicine-Based Clinical Research Studies for Fatal Disorders. Human Gene Therapy, 2005, 16, 1028-1036.	1.4	33
79	Safety of Direct Administration of AAV2CUhCLN2, a Candidate Treatment for the Central Nervous System Manifestations of Late Infantile Neuronal Ceroid Lipofuscinosis, to the Brain of Rats and Nonhuman Primates. Human Gene Therapy, 2005, 16, 1484-1503.	1.4	49
80	Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the HumanCLN2cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy, 2004, 15, 1131-1154.	1.4	118
81	Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human<I> CLN2</I> cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis. Human Gene Therapy, 2004, 15, 1131-1154.	1.4	9
82	Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive Individuals. AIDS Research and Human Retroviruses, 2000, 16, 337-343.	0.5	33
83	Reduction of thioredoxin significantly decreases its partial specific volume and adiabatic compressibility. Protein Science, 1992, 1, 22-30.	3.1	24
84	Inhibition of the Na+/I- symporter by harmaline and 3-amino-1-methyl-5H-pyrido(4,3-b)indole acetate in thyroid cells and membrane vesicles. FEBS Journal, 1991, 200, 203-207.	0.2	19
85	Long Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Non-human Primates for the Treatment of Late Infantile Neuronal Lipofuscinosis. Human Gene Therapy Methods, 0, , 121017063203000.	2.1	0
86	Safety of Direct Cardiac Administration of AdVEGF-All6A+, a Replication Deficient Adenovirus Vector cDNA/Genomic Hybrid Expressing All Three Major Isoforms of Human Vascular Endothelial Growth Factor, to the Ischemic Myocardium of Rats. Human Gene Therapy Clinical Development, 0, , 130514071334005.	3.2	0
87	Fate of Systemically Administered Cocaine in Nonhuman Primates Treated with the dAd5GNE Anti-cocaine Vaccine. Human Gene Therapy Clinical Development, 0, , 150127063140004.	3.2	1